View Older Stories

Mar 18, 2026 09:21AM RBC Capital on Biopharma: 'M&A Discussion, Whether Accurate Or Not, Can Drive Returns'

Mar 9, 2026 12:34PM Baird on Dyne Therapeutics (DYN): 'Positive on clinical progress and improved regulatory dynamic'

Mar 9, 2026 11:55AM Jones Trading Reiterates Buy Rating on Dyne Therapeutics (DYN): "should clinch accelerated approval in the US"

Mar 9, 2026 11:45AM Stifel Reiterates Buy Rating on Dyne Therapeutics (DYN) following 2026 MDA conference

Mar 9, 2026 11:06AM Jones on Dyne Amid 14pct Gain: 'MDA'26: Best-in-Class DMD Program Looks Even Better'

Mar 9, 2026 10:29AM Stifel on Dyne Therapeutics Inc. (DYN): 'Longer-term Data At MDA Support DYNE-251's Strong DMD Profile'

Mar 9, 2026 09:22AM Jefferies on Dyne Therapeutics (DYN): 'We remain 70-80%+ confident in an AA approval by Q1:27'

Mar 9, 2026 05:26AM Dyne reports heart and lung function improvements in DMD trial

Mar 3, 2026 07:22AM Dyne Therapeutics (DYN) PT Lowered to $50 at H.C. Wainwright

Mar 2, 2026 05:37PM Chardan Reiterates Buy Rating on Dyne Therapeutics (DYN)

Mar 2, 2026 02:37PM Raymond James Reiterates Strong Buy Rating on Dyne Therapeutics (DYN)

Mar 2, 2026 11:12AM Dyne Therapeutics (DYN) PT Lowered to $47 at Morgan Stanley

Mar 2, 2026 08:39AM Dynegy (DYN) Tops Q4 EPS by 1c

Jan 20, 2026 07:30AM Dyne Therapeutics receives orphan drug designation in Japan for DM1 treatment

Dec 10, 2025 06:54AM Oppenheimer Upgrades Dyne Therapeutics (DYN) to Outperform

Dec 9, 2025 07:40AM Dyne Therapeutics (DYN) PT Raised to $23 at Bernstein SocGen Group

Dec 8, 2025 04:57PM After-hours movers: NVIDIA, Toll Brothers, and more

Dec 8, 2025 12:06PM Dyne Therapeutics (DYN) PT Raised to $50 at Morgan Stanley

Dec 8, 2025 09:27AM Dyne Therapeutics (DYN) PT Raised to $60 at H.C. Wainwright

Dec 8, 2025 09:26AM Baird Reiterates Outperform Rating on Dyne Therapeutics (DYN)

Dec 8, 2025 07:40AM Dyne Therapeutics (DYN) PT Raised to $40 at Raymond James

Nov 27, 2025 02:00AM Bernstein sees favorable risk-reward in this biotech stock

Nov 25, 2025 07:30AM Dyne Therapeutics (DYN) PT Raised to $21 at Bernstein SocGen Group, we see risk-reward as favorable

Nov 16, 2025 03:00PM Where can biotech stocks go from here? RBC answers

Nov 5, 2025 05:56PM Dynegy (DYN) Tops Q3 EPS by 8c

Oct 24, 2025 08:29AM Piper Sandler: 'Biotech Has a Heartbeat: 17 Stocks to Own Through YE25'

Oct 10, 2025 06:04AM Oppenheimer Downgrades Dyne Therapeutics (DYN) to Perform

Sep 29, 2025 08:35AM Dyne Therapeutics gets orphan drug status in Japan for DMD therapy

Sep 29, 2025 07:57AM Piper Sandler: 'Own Dyne Therapeutics (DYN) for DELIVER Data in Late 2025'

Sep 11, 2025 08:18AM RBC Capital on Biotech Shares: 'Company-Specific Volatility For Quality Names May Be Overdone'

Aug 25, 2025 06:05AM Raymond James Upgrades Dyne Therapeutics (DYN) to Strong Buy

Aug 6, 2025 11:20AM Dyne Therapeutics Inc. (DYN) gains following Avidity Biosciences Inc. (RNA) Takeover Rumors, Up 24%

Aug 4, 2025 08:31AM Stifel Reiterates Buy Rating on Dyne Therapeutics (DYN)

Jul 30, 2025 04:40PM Dyne Therapeutics (DYN) PT Lowered to $36 at Stifel

Jul 28, 2025 04:40PM Dynegy (DYN) Misses Q2 EPS by 3c

Jul 2, 2025 07:41AM Dyne Therapeutics (DYN) PT Lowered to $11.50 at Bernstein

Jun 30, 2025 04:05PM Dyne Therapeutics Inc. (DYN) Announces Proposed $200M Share Offering

Jun 30, 2025 04:02PM Dyne Therapeutics (DYN) Secures Up to $275 Million in Debt Financing from Hercules Capital

Jun 25, 2025 04:12PM Jones Trading Starts Dyne Therapeutics (DYN) at Buy

Jun 18, 2025 06:43AM H.C. Wainwright Reiterates Buy Rating on Dyne Therapeutics (DYN)

Jun 17, 2025 09:39AM Chardan Capital Markets Reiterates Buy Rating on Dyne Therapeutics (DYN) Following FDA Update

Jun 17, 2025 07:01AM Dyne Therapeutics (DYN) Announces FDA Breakthrough Therapy Designation for DYNE-101 and Updated Plan for Accelerated Approval in DM1 Following Type C Meeting

Jun 5, 2025 12:44PM FDA Cell and Gene Therapy Roundtable 'bullish for the space' - Stifel

Jun 2, 2025 08:52AM Oppenheimer Assumes Dyne Therapeutics (DYN) at Outperform (correction)

May 29, 2025 06:15AM Evercore ISI Starts Dyne Therapeutics (DYN) at Outperform

May 13, 2025 02:22PM Stifel Reiterates Buy Rating on Dyne Therapeutics (DYN), PT $66

May 12, 2025 06:57AM Dyne Therapeutics (DYN) PT Lowered to $38 at H.C. Wainwright

May 8, 2025 05:27PM Dynegy (DYN) Misses Q1 EPS by 20c

Apr 24, 2025 07:32AM Dyne Therapeutics Inc. (DYN) Receives European Medicines Agency (EMA) Orphan Drug Designation for DYNE-251 in Duchenne Muscular Dystrophy

Apr 15, 2025 07:31AM Dyne Therapeutics Inc. (DYN) Announces Chief Business Officer and Chief Scientific Officer Appointments

View Older Stories